Acquires Menarini group Invida.
Singapore, Florence, November 2011- Singapore, Australia, China, Hong Kong, India, Indonesia, Malaysia, New Zealand, Korea South, Taiwan, Thailand, Philippines and Viet Nam. These are the countries which opens the Italian multinational headquartered in Florencia, Menarini group, following the signing in Singapore of the contract for Invida Group Private Limited (Invida), until now in the hands of Temased Holding (a company of Asian investment Singapore-based), Quintiles (North American biotechnology and pharmacy services company) and Zuelling (leader in distribution of health in Asia).
Invida group is one of the major pharmaceutical companies with activity in the Asia Pacific region, an area which represents 10% of the global pharmaceutical market, and has a 20% annual growth. With a turnover of more than 220 million dollars (160 million euros) annually, it employs 3,500 people in template and a consolidated presence in major therapeutic areas. Invida to Menarini represents the most suitable company for your opening emerging countries with the highest rates of growth in the world. The financial terms of the transaction have not been revealed.
Development model provided by Menarini for group Invida provides, as in all purchases above, assess the identity, culture and local competences, and thus ensures Invida and its human resources based on a highly entrepreneurial vision future, dynamic and not speculative.
Has been a challenging negotiations to which we have worked in full in recent months ” said Alberto Giovanni Aleotti, together with the director general Piero Corsa has guided the negotiating team of Menarini. Also on this occasion our team has worked with extraordinary passion, and I take this opportunity to thank each Member of the same heart ”. For Aleotti: Singapore perceives the vitality of all the countries of the area and focus the best skills, thanks to policies with a vision for the future of the Governments of the area ”.
En Invida have found the Menarini of Asia, and a management with exceptional powers ”, discussed Piero Corsa and Domenico Simone, CEOs of Menarini, underlining the potential of the acquisition: have a headquarters in Singapore is ideal to create a bridge between Europe and Asia and to Asian patients carry that way all the therapeutic benefits of our medicines ”.
John Graham, CEO of Invida to continue conducting activities in the Asia Pacific area.
Lucia Aleotti, Vice-President of the Menarini group has concluded: this challenge we are excited about, because one side puts us before great opportunities for expansion in rapidly developing countries, and on the other hand, our group will bring new highly qualified ”.
About Menarini
Menarini group is the leading Italian pharmaceutical group in the world, settling in the 15th place of 4.881 European companies and ranked 34 of 14.051 companies in the world by turnover, according to data from 2010. Last year the company invoiced 3,031 million euros. The company employs 12.890 workers, of which 91% are graduates and technical specialists. Menarini group has always pursued two strategic objectives: research and internationalization. both targets have enabled Menarini results highlighted in the global market; as well as reinvested in research and innovation of new drugs, making them available to patients around the world.
With a presence in over 100 countries, Menarini group is responsible for the needs of patients and specialist health care in the following therapeutic areas: cardiovascular, Gastroenterology, antibiotics, in the respiratory field, products for the treatment of diabetes, anti-inflammatory drugs and analgesics.
On group Invida
Invida improves the lives of the patients in Asia through the marketing of prescription drugs and pharmaceutical advertising specialties (EFP). As a result of this acquisition, all shareholders will grow with the company. All this has been a careful plan of brand marketing and a know-how applied to sales, combined with extensive experience in therapeutic areas key and deep knowledge of the Asian market.
About 3,500 employees in 13 Asia-Pacific markets, Invida operates throughout the production chain from regulatory to launch the product approval through the management of the life of the drug. Manages a broad participation in other brands of products approved, from small to large biotech companies and health multinational. Partnering is the key to the business model of Invida. It works closely with partners, to develop effective strategies and putting his extensive experience as a backup to maximize the assets entrusted to them.
